449 related articles for article (PubMed ID: 21146713)
1. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
Pfaller MA; Messer SA; Jones RN; Castanheira M
J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
[TBL] [Abstract][Full Text] [Related]
4. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
5. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
6. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
7. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
9. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
10. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).
Messer SA; Moet GJ; Kirby JT; Jones RN
J Clin Microbiol; 2009 Jun; 47(6):1942-6. PubMed ID: 19386851
[TBL] [Abstract][Full Text] [Related]
11. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
13. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):278-83. PubMed ID: 20846808
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
16. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
[TBL] [Abstract][Full Text] [Related]
17. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).
Messer SA; Jones RN; Moet GJ; Kirby JT; Castanheira M
J Clin Microbiol; 2010 Aug; 48(8):2984-7. PubMed ID: 20534798
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
[TBL] [Abstract][Full Text] [Related]
19. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Espinel-Ingroff A; Cantón E
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():3-9. PubMed ID: 21420570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
